Thus, in multiple tumor models immunoliposome therapy maintained the anti-tumor efficacy but eliminated multiple features of the systemic toxicity elicited by free IL-2-Fc + anti-CD137 treatment. This evidence concerns the gene IL2 and neoplasm.